Search

Your search keyword '"Bayne, Mike"' showing total 10 results
Start Over Author "Bayne, Mike" Search Limiters Full Text
10 results on '"Bayne, Mike"'

2. Infinite-order diagrammatic summation approach to explicitly correlated congruent transformed Hamiltonian

Author

Bayne, Mike, Drogo, John, and Chakraborty, Arindam

Subjects
Physics - Chemical Physics
Abstract

A resolution of identity approach to explicitly correlated congruent transformed Hamiltonian (CTH) is presented. One of the principle challenges associated with the congruent transformation of the many-electron Hamiltonian is the generation of three, four, five, and six particle operators. Successful application of the congruent transformation requires efficient implementation of the many-particle operators. In this work, we present the resolution of identity congruent transformed Hamiltonian (RI-CTH) method to handle many-particle operators. The resolution of identity was used to project the explicitly correlated operator in a N-particle finite basis to avoid explicit computation of the many-particle operators. Single-particle states were obtained by performing Hartee-Fock calculations, which were then used for construction of many-particle states. The limitation of the finite nature of the resolution of identity was addressed by developing partial infinite order (PIOS) diagrammatic summation technique. In the PIOS method, the matrix elements of the projected congruent transformed Hamiltonian was expressed in terms of diagrammatic notation and a subset of diagrams were summed up to infinite order. The RI-CTH and RI-CTH-PIOS methods were applied to isoelectronic series of 10-electron systems (Ne,HF,H2O,NH3,CH4) and results were compared with CISD and CCSD(T) calculations. One of the key results from this work is that for identical basis set, the RI-CTH-PIOS energies are lower than CISD and CCSD(T) values., Comment: 6 pages

Published
2013
Full Text
View/download PDF

5. Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sezary syndrome and those with more extensive skin involvement

Author

Molloy, Kevin Evison, Felicity Peng, Chenjing Guenova, Emmanuella Cowan, Richard Busschots, Annemie Woei-A-Jin, Sherida H. Bervoets, An Hauben, Esther Beylot-Barry, Marie and Jonak, Constanze Knobler, Robert Pokert, Stefanie and Papadavid, Evangelina Vakeva, Liisa Matin, Rubeta Bates, Andrew Estrach, Teresa Prince, Miles Twigger, Robert and Berti, Emilio Violetti, Silvia Alberti Bayne, Mike McKay, Pam Wachsmuch, Rachel Akilov, Oleg McCann, Susan and Damasco, Fabiana Sanches, Jose Antonio Miyashiro, Denis and Cury-Martins, Jade Turner, Deborah Wobser, Marion Benstead, Kim Yoo, Jinah Scarisbrick, Julia

Published
2018

6. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss

Author

Crabb, Simon J., Martin, Karen, Abab, Julia, Ratcliffe, Ian, Thornton, Roger, Lineton, Ben, Ellis, Mary, Moody, Ronald, Stanton, Louise, Galanopoulou, Angeliki, Maishman, Tom, Geldart, Thomas, Bayne, Mike, Davies, Joe, Lamb, Carolynn, Popat, Sanjay, Joffe, Johnathan K., Nutting, Chris, Chester, John, Hartley, Andrew, Thomas, Gareth, Ottensmeier, Christian, Huddart, Robert, and King, Emma

Subjects
Adult, Male, RM, Time Factors, TINNITUS, Antineoplastic Agents, Protective Agents, Article, Drug Administration Schedule, TESTICULAR CANCER, RC0254, Young Adult, Hearing, Double-Blind Method, Neoplasms, otorhinolaryngologic diseases, Chemotherapy, Humans, Oncology & Carcinogenesis, Hearing Loss, Aged, SURVIVORS, Science & Technology, Aspirin, Middle Aged, Ototoxicity, United Kingdom, Treatment Outcome, Oncology, Cytoprotection, RADIATION, Audiometry, Pure-Tone, Female, Cisplatin, Life Sciences & Biomedicine, 1112 Oncology And Carcinogenesis
Abstract

Background Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has been shown to minimise gentamicin-induced ototoxicity. We, therefore, tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy. Methods A total of 94 patients receiving cisplatin-based chemotherapy for multiple cancer types were recruited into a phase II, double-blind, placebo-controlled trial and randomised in a ratio of 1:1 to receive aspirin 975 mg tid and omeprazole 20 mg od, or matched placebos from the day before, to 2 days after, their cisplatin dose(s), for each treatment cycle. Patients underwent pure tone audiometry before and at 7 and 90 days after their final cisplatin dose. The primary end-point was combined hearing loss (cHL), the summed hearing loss at 6 kHz and 8 kHz, in both ears. Results Although aspirin was well tolerated, it did not protect hearing in patients receiving cisplatin (p-value = 0.233, 20% one-sided level of significance). In the aspirin arm, patients demonstrated mean cHL of 49 dB (standard deviation [SD] 61.41) following cisplatin compared with placebo patients who demonstrated mean cHL of 36 dB (SD 50.85). Women had greater average hearing loss than men, and patients treated for head and neck malignancy experienced the greatest cHL. Conclusions Aspirin did not protect from cisplatin-related ototoxicity. Cisplatin and gentamicin may therefore have distinct ototoxic mechanisms, or cisplatin-induced ototoxicity may be refractory to the aspirin regimen used here., Highlights • Aspirin was well tolerated. • Aspirin did not protect hearing at the doses and in the schedule investigated here. • Cisplatin and gentamicin may have distinct ototoxic mechanisms. • Qualitative data suggest protective aspirin effect but low power for hypothesis. • Cisplatin-induced ototoxicity results in significant morbidity.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results